Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: A prospective clinical trial

Head and Neck

Volumn 33, Issue 7, 2011, Pages 935-940

  Rudmik, Luke ^a   Lau, Harold Y ^a   Matthews, T Wayne ^a   Bosch, J Douglas ^a   Kloiber, Reinhard ^a   Molnar, Christine P ^a   Dort, Joseph C ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

clinical utility; head and neck imaging; head and neck squamous cell carcinoma; PET CT; unknown primary

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER OF UNKNOWN PRIMARY SITE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; PROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79959209221     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21566     Document Type: Article

References (19)

1. Galer CE, Kies MS,. Evaluation and management of the unknown primary carcinoma of the head and neck. J Natl Compr Canc Netw 2008; 6: 1068-1075.
2. Grau C, Johansen LV, Jakobsen J, Geertsen P, Andersen E, Jensen BB,. Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology. Radiother Oncol 2000; 55: 121-129. (Pubitemid 30229986)
3. Jereczek-Fossa BA, Jassem J, Orecchia R,. Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat Rev 2004; 30: 153-164. (Pubitemid 38418053)
4. Miller FR, Karnad AB, Eng T, Hussey DH, Stan McGuff H, Otto RA,. Management of the unknown primary carcinoma: long-term follow-up on a negative PET scan and negative panendoscopy. Head Neck 2008; 30: 28-34. (Pubitemid 351158318)
5. Jones AS, Cook JA, Phillips DE, Roland NR,. Squamous carcinoma presenting as an enlarged cervical lymph node. Cancer 1993; 72: 1756-1761. (Pubitemid 23249307)
6. Cianchetti M, Mancuso AA, Amdur RJ, et al. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Laryngoscope 2009; 119: 2348-2354.
7. Mendenhall WM, Mancuso AA, Parsons JT, Stringer SP, Cassisi NJ,. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck 1998; 20: 739-744. (Pubitemid 28462831)
8. Johansen J, Buus S, Loft A, et al. Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck 2008; 30: 471-478. (Pubitemid 351578750)
9. Seve P, Billotey C, Broussolle C, Dumontet C, Mackey JR,. The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 2007; 109: 292-299. (Pubitemid 46116455)
10. Al-Ibraheem A, Buck A, Krause BJ, Scheidhauer K, Schwaiger M,. Clinical applications of FDG PET and PET/CT in head and neck cancer. J Oncol 2009; 208725: 1-13.
11. Rusthoven KE, Koshy M, Paulino AC,. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 2004; 101: 2641-2649. (Pubitemid 39532297)
12. Fleming AJ Jr, Smith SP Jr, Paul CM, et al. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients. Laryngoscope 2007; 117: 1173-1179. (Pubitemid 47015665)
13. Wartski M, Le Stanc E, Gontier E, et al. In search of an unknown primary tumour presenting with cervical metastases: performance of hybrid FDG-PET/CT. Nucl Med Commun 2007; 28: 365-371. (Pubitemid 46569169)
14. Freidlin B, Korn EL,. Stopping clinical trials early for benefit: impact on estimation. Clin Trials 2009; 6: 119-125.
15. Freidlin B, Korn EL,. Monitoring for lack of benefit: a critical component of a randomized clinical trial. J Clin Oncol 2009; 27: 629-633.
16. Roh JL, Kim JS, Lee JH, et al. Utility of combined (18)F- fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors. Oral Oncol 2009; 45: 218-224.
17. Freidlin B, Korn EL, George SL,. Data monitoring committees and interim monitoring guidelines. Control Clin Trials 1999; 20: 395-407. (Pubitemid 29460917)
18. Koch WM, Bhatti N, Williams MF, Eisele DW,. Oncologic rationale for bilateral tonsillectomy in head and neck squamous cell carcinoma of unknown primary source. Otolaryngol Head Neck Surg 2001; 124: 331-333. (Pubitemid 32230530)
19. McQuone SJ, Eisele DW, Lee DJ, Westra WH, Koch WM,. Occult tonsillar carcinoma in the unknown primary. Laryngoscope 1998; 108: 1605-1610.